Company intelligence / Profile preview

THERYQ

Peynier, France

Ownership: Private
Development stage: Other

Overview

THERYQ develops FLASH radiotherapy systems delivering ultra-high dose rates in milliseconds to treat tumors with reduced damage to healthy tissues. First patient treated in 2018; clinical trials for FLASHKNiFE ongoing, with CE Mark targeted for 2026 and FDA for 2027[1][3][4].

Therapeutic areas: Oncology
Industry: Therapeutic Medical Devices

Partnerships

CERNGustave RoussyCHUV (Lausanne University Hospital)Leo Cancer CareUZ BrusselEIT HealthFrance 2030

Beyond the preview

Go deeper on THERYQ.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on THERYQ.

Explore the full profile